Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Seminars in Immunopathology
Published in: Seminars in Immunopathology 2/2013

01-03-2013 | Review

The role of PGE2-associated inflammatory responses in gastric cancer development

Authors: Hiroko Oshima, Masanobu Oshima

Published in: Seminars in Immunopathology | Issue 2/2013

Login to get access

Abstract

Accumulating evidence indicates that inflammation plays a critical role in cancer development. Cyclooxygenase-2 (COX-2) is a rate-limiting enzyme for prostanoid biosynthesis, including prostaglandin E2 (PGE2), and plays a key role in both inflammation and cancer. It has been demonstrated that inhibition of COX-2 and PGE2 receptor signaling results in the suppression of tumor development in a variety of animal models. However, the molecular mechanisms underlying COX-2/PGE2-associated inflammation in carcinogenesis have not yet been fully elucidated. In order to study the role of PGE2-associated inflammatory responses in tumorigenesis, it is important to use in vivo mouse models that recapitulate human cancer development from molecular mechanisms with construction of tumor microenvironment. We have developed a gastritis model (K19-C2mE mice) in which an inflammatory microenvironment is constructed in the stomach via induction of the COX-2/PGE2 pathway. We also developed a gastric cancer mouse model (Gan mice) in which the mice develop inflammation-associated gastric tumors via activation of both the COX-2/PGE2 pathway and Wnt signaling. Expression analyses using these in vivo models have revealed novel mechanisms of the inflammatory responses underlying gastric cancer development. PGE2-associated inflammatory responses activate epidermal growth factor receptor (EGFR) signaling through the induction of EGFR ligands and ADAMs that release EGFR ligands from the cell membrane. In Gan mice, a combination treatment with EGFR and COX-2 inhibitors significantly suppresses gastric tumorigenesis. Moreover, PGE2-associated inflammation downregulates tumor suppressor microRNA, miR-7, in gastric cancer cells, which suppresses epithelial differentiation. These results indicate that PGE2-associated inflammatory responses promote in vivo gastric tumorigenesis via several different molecular mechanisms.
Literature
1.
Kuper H, Adami HO, Trichopoulos D (2000) Infections as a major preventable cause of human cancer. J Intern Med 248:171–183PubMedCrossRef
2.
Parkin DM (2006) The global health burden of infection-associated cancers in the year 2002. Int J Cancer 118:3030–3044PubMedCrossRef
3.
Takahashi H, Ogata H, Nishigaki R, Broide DH, Karin M (2010) Tobacco smoke promotes lung tumorigenesis by triggering IKKβ- and JNK1-dependent inflammation. Cancer Cell 17:89–97PubMedCrossRef
4.
Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, Osterreicher CH, Takahashi H, Karin M (2010) Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140:197–208PubMedCrossRef
5.
6.
Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454:436–444PubMedCrossRef
7.
8.
9.
Wang D, DuBois RN (2010) The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene 29:781–788PubMedCrossRef
10.
Li HJ, Reinhardt F, Herschman HR, Weinberg RA (2012) Cancer-stimulated mesenchymal stem cells create a carcinoma stem-cell niche via prostaglandin E2 signaling. Cancer Discov 2:840–855
11.
Oshima H, Oguma K, Du YC, Oshima M (2009) Prostaglandin E2, Wnt, and BMP in gastric tumor mouse models. Cancer Sci 100:1779–1785PubMedCrossRef
12.
Oshima H, Oshima M (2010) Mouse models of gastric tumors: Wnt activation and PGE2 induction. Pathol Int 60:599–607PubMedCrossRef
13.
Thun MJ, Namboodiri MM, Heath CW Jr (1991) Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325:1593–1596PubMedCrossRef
14.
Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC, Speizer FE (1995) Aspirin and the risk of colorectal cancer in women. N Engl J Med 333:609–614PubMedCrossRef
15.
Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV, Robinson CR, Offerhaus GJ (1993) Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328:1313–1316PubMedCrossRef
16.
Oshima M, Taketo MM (2002) COX selectivity and animal models for colon cancer. Curr Pharm Des 8:1021–1034PubMedCrossRef
17.
Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Trzaskos JM, Evans JF, Taketo MM (1996) Suppression of intestinal polyposis in Apc∆716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87:803–809PubMedCrossRef
18.
Chulada PC, Thompson MB, Mahler JF, Doyle CM, Gaul BW, Lee C, Tiano HF, Morham SG, Smithies O, Langenbach R (2000) Genetic disruption of Ptgs-1, as well as of Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 60:4705–4708PubMed
19.
Yoshimatsu K, Altorki NK, Golijanin D, Zhang F, Jakobsson PJ, Dannenberg AJ, Subbaramaiah K (2001) Inducible prostaglandin E synthase is overexpressed in non-small cell lung cancer. Clin Cancer Res 7:2669–2674PubMed
20.
van Rees BP, Sivula A, Thoren S, Yokozaki H, Jalobsson PJ, Offerhaus GJ, Ristimaki A (2003) Expression of microsomal prostaglandin E synthase-1 in intestinal gastric adenocarcinoma and in gastric cancer cell lines. Int J Cancer 107:551–556PubMedCrossRef
21.
Nakanishi M, Montrose DC, Clark P, Nambiar PR, Belinsky GS, Claffey KP, Xu D, Rosenberg DW (2008) Genetic deletion of mPGES-1 suppresses intestinal tumorigenesis. Cancer Res 68:3251–3259PubMedCrossRef
22.
Nakanishi M, Menoret A, Tanaka T, Miyamoto S, Montrose DC, Vella AT, Rosenberg DW (2011) Selective PGE2 suppression inhibits colon carcinogenesis and modifies local mucosal immunity. Cancer Prev Res 4:1198–1208CrossRef
23.
Sonoshita M, Takaku K, Sasaki N, Sugimoto Y, Ushikubi F, Natumiya S, Oshima M, Taketo MM (2001) Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc∆716 knockout mice. Nat Med 7:1048–1051PubMedCrossRef
24.
Seno H, Oshima M, Ishikawa TO, Oshima H, Takaku K, Chiba T, Narumiya S, Taketo MM (2002) Cyclooxygenase 2- and prostaglandin E2 receptor EP2-dependent angiogenesis in Apc∆716 mouse intestinal polyps. Cancer Res 62:506–511PubMed
25.
Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS (2005) Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin–β-catenin signaling axis. Science 310:1504–1510PubMedCrossRef
26.
27.
Moore RJ, Owens DM, Stamp G, Arnott C, Burke F, East N, Holdsworth H, Turner L, Rollins B, Pasparakis M, Kollias G, Balkwill F (1999) Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesis. Nat Med 5:828–831PubMedCrossRef
28.
Arnott CH, Scott KA, Moore RJ, Robinson SC, Thompson RG, Balkwill FR (2004) Expression of both TNF-α receptor subtypes is essential for optimal skin tumor development. Oncogene 23:1902–1910PubMedCrossRef
29.
Popivanova BK, Kitamura K, Wu Y, Kondo T, Kagaya T, Kaneko S, Oshima M, Fujii C, Mukaida N (2008) Blocking TNF-α in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest 118:560–570PubMed
30.
Oshima H, Oshima M (2012) The inflammatory network in the gastrointestinal tumor microenvironment: lessons from mouse models. J Gastroenterol 47:97–106PubMedCrossRef
31.
Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, Kagnoff MF, Karin M (2004) IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118:285–296PubMedCrossRef
32.
Heikkila K, Ebrahim S, Lawlor DA (2008) Systematic review of the association between circulating interleukin-6 (IL-6) and cancer. Eur J Cancer 44:937–945PubMedCrossRef
33.
Bollrath J, Phesse TJ, von Burstin VA, Putoczki T, Bennecke M, Bateman T, Nebelsiek T, Lundgren-May T, Canli O, Schwitala S, Matthews V, Schmid RM, Kirchner T, Arkan MC, Ernst M, Greten FR (2009) gp130-mediated STAT3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 15:91–102PubMedCrossRef
34.
Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, Scheller J, Rose-John S, Cheroutre H, Eckmann L, Karin M (2009) IL-6 and STAT3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15:103–113PubMedCrossRef
35.
Gregorieff A, Clevers H (2005) Wnt signaling in the intestinal epithelium: from endoderm to cancer. Genes Dev 19:877–890PubMedCrossRef
36.
Taketo MM (2006) Wnt signaling and gastrointestinal tumorigenesis in mouse models. Oncogene 25:7522–7530PubMedCrossRef
37.
Oshima M, Oshima H, Kitagawa K, Kobayashi M, Itakura C, Taketo M (1995) Loss of Apc heterozygosity and abnormal tissue building in nascent intestinal polyps in mice carrying a truncated Apc gene. Proc Natl Acad Sci USA 92:4482–4486PubMedCrossRef
38.
Harada N, Tamai Y, Ishikawa T, Sauer B, Takaku K, Oshima M, Taketo MM (1999) Intestinal polyposis in mice with a dominant stable mutation of the β-catenin gene. EMBO J 18:5931–5942PubMedCrossRef
39.
Clements WM, Wang J, Sarnaik A, Kim OJ, MacDonald J, Fenoglio-Preiser C, Groden J, Lowy AM (2002) β-Catenin mutation is a frequent cause of Wnt pathway activation in gastric cancer. Cancer Res 62:3503–3506PubMed
40.
Woo DK, Kim HS, Lee HS, Kang YH, Yang HK, Kim WH (2001) Altered expression and mutation of β-catenin gene in gastric carcinomas and cell lines. Int J Cancer 95:108–113PubMedCrossRef
41.
Cheng XX, Wang ZC, Chen XY, Sun Y, Kong QY, Liu J, Li H (2005) Correlation of Wnt-2 expression and β-catenin intracellular accumulation in Chinese gastric cancers: relevance with tumour dissemination. Cancer Lett 223:339–347PubMedCrossRef
42.
Oshima H, Matsunaga A, Fujimura T, Tsukamoto T, Taketo MM, Oshima M (2006) Carcinogenesis in mouse stomach by simultaneous activation of the Wnt signaling and prostaglandin E2 pathway. Gastroenterology 131:1086–1095PubMedCrossRef
43.
Park WS, Oh RR, Park JY, Lee SH, Shin MS, Kim YS, Kim SY, Lee HK, Kim PJ, Oh ST, Yoo NJ, Lee JY (1999) Frequent somatic mutations of the β-catenin gene in intestinal-type gastric cancer. Cancer Res 59:4257–4260PubMed
44.
Ebert MP, Fei G, Kahmann S, Muller O, Yu J, Sung JJ, Malfertheiner P (2002) Increased β-catenin mRNA levels and mutational alterations of the APC and β-catenin gene are present in intestinal-type gastric cancer. Carcinogenesis 23:87–91PubMedCrossRef
45.
Oguma K, Oshima H, Aoki M, Uchio R, Naka K, Nakamura S, Hirao A, Saya H, Taketo MM, Oshima M (2008) Activated macrophages promote Wnt signalling through tumour necrosis factor-α in gastric tumour cells. EMBO J 27:1671–1681PubMedCrossRef
46.
Ristimäki A, Honkanen N, Jänkälä H, Sipponen P, Härkönen M (1997) Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 57:1276–1280PubMed
47.
Al-Marhoon MS, Nunn S, Soames RW (2004) CagA + Helicobacter pylori induces greater levels of prostaglandin E2 than cagA − strains. Prostaglandins Other Lipid Mediat 73:181–189PubMedCrossRef
48.
Sun WH, Yu Q, Shen H, Qu XL, Cao DZ, Yu T, Qian C, Zhu F, Sun YL, Fu XL, Su H (2004) Roles of Helicobacter pylori infection and cyclooxygenase-2 expression in gastric carcinogenesis. World J Gastroenterol 10:2809–2813PubMed
49.
Oshima H, Oshima M, Inaba K, Taketo MM (2004) Hyperplastic gastric tumors induced by activated macrophages in COX-2/mPGES-1 transgenic mice. EMBO J 23:1669–1678PubMedCrossRef
50.
Oshima M, Ohima H, Matsunaga A, Taketo MM (2005) Hyperplastic gastric tumors with spasmolytic polypeptide-expressing metaplasia caused by tumor necrosis factor-α-dependent inflammation in cyclooxygenase-2/microsomal prostaglandin E synthase-1 transgenic mice. Cancer Res 65:9147–9151PubMedCrossRef
51.
Yamaguchi H, Goldenring JR, Kaminishi M, Lee JR (2002) Identification of spasmolytic polypeptide-expressing metaplasia (SPEM) in remnant gastric cancer and surveillance post-gastrectomy biopsies. Dig Dis Sci 47:573–578PubMedCrossRef
52.
Halldorsdottir AM, Sigurdardottrir M, Jonasson JG, Oddsdottir M, Magnusson J, Lee JR, Goldenring JR (2003) Spasmolytic polypeptide-expressing metaplasia (SPEM) associated with gastric cancer in Iceland. Dig Dis Sci 48:431–441PubMedCrossRef
53.
Goldenring JR, Nomura S (2009) Insight into the development of preneoplastic metaplasia: spasmolytic polypeptide-expressing metaplasia and oxyntic atrophy. In: Wang TC, Fox JG, Giraud AS (eds) The biology of gastric cancer. Springer, New York, pp 361–375CrossRef
54.
Nomura S, Baxter T, Yamaguchi H, Leys C, Vartapetian AB, Fox JG, Lee JR, Wang TC, Goldenring JR (2004) Spasmolytic polypeptide expressing metaplasia to preneoplasia in H. felis-infected mice. Gastroenterology 127:582–594PubMedCrossRef
55.
Kang W, Rathinavelu S, Samuelson LC, Merchang JL (2005) Interferon γ induction of gastric mucous neck cell hypertrophy. Lab Invest 85:702–715PubMedCrossRef
56.
Judd LM, Alderman BM, Howlett M, Shulkes A, Dow C, Moverley J, Grail D, Jenkins BJ, Ernst M, Giraud AS (2004) Gastric cancer development in mice lacking the SHP2 binding site on the IL-6 family co-receptor gp130. Gastroenterology 126:196–207PubMedCrossRef
57.
Guo X, Oshima H, Kitamura T, Taketo MM, Oshima M (2008) Stromal fibroblasts activated by tumor cells promote angiogenesis in mouse gastric cancer. J Biol Chem 283:19864–19871PubMedCrossRef
58.
Itadani H, Oshima H, Oshima M, Kotani H (2009) Mouse gastric tumor models with prostaglandin E2 pathway activation show similar gene expression profiles to intestinal-type human gastric cancer. BMC Genomics 10:615PubMedCrossRef
59.
Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H, Oshima M, Ikeda T, Asaba R, Yagi H, Masuko T, Shimizu T, Ishikawa T, Kai K, Takahashi E, Imamura Y, Baba Y, Ohmura M, Suematsu M, Baba E, Saya H (2011) CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of xc− and thereby promotes tumor growth. Cancer Cell 19:387–400PubMedCrossRef
60.
Ishimoto T, Oshima H, Oshima M, Kai K, Torii R, Masuko T, Baba H, Saya H, Nagano O (2010) CD44(+) slow-cycling tumor cell expansion is triggered by cooperative actions of Wnt and prostaglandin E2 in gastric tumorigenesis. Cancer Sci 101:673–678PubMedCrossRef
61.
Oshima H, Hioki K, Popivanova BK, Oguma K, van Rooijen N, Ishikawa T, Oshima M (2011) Prostaglandin E2 signaling and bacterial infection recruit tumor-promoting macrophages to mouse gastric tumors. Gastroenterology 140:596–607PubMedCrossRef
62.
Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R (2004) Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 118:229–241PubMedCrossRef
63.
Rakoff-Nahoum S, Medzhitov R (2007) Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science 317:124–127PubMedCrossRef
64.
Chinen T, Komai K, Muto G, Morita R, Inoue N, Yoshida H, Sekiya T, Yoshida R, Nakamura K, Takayanagi R, Yoshimura A (2010) Prostaglandin E2 and SOCS1 have a role in intestinal immune tolerance. Nature Commun 2:190CrossRef
65.
Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, DuBois RN (2005) Cyclooxigenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 2:254–266CrossRef
66.
Roberts RB, Min L, Washington MK, Olsen SJ, Settle SH, Coffey RJ, Threadgill DW (2002) Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis. Proc Natl Acad Sci USA 99:1521–1526PubMedCrossRef
67.
Torrance CJ, Jackson PE, Montgomery E, Kinzler KW, Vogelstein B, Wissner A, Nunes M, Frost P, Discafani CM (2006) Combinatorial chemoprevention of intestinal neoplasia. Nat Med 6:1024–1028
68.
Buchanan FG, Holla V, Katkuri S, Matta P, DuBois RN (2008) Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer. Cancer Res 67:9380–9388CrossRef
69.
Buchanan FG, Wang D, Bargiacchi F, DuBois RN (2003) Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem 278:35451–35457PubMedCrossRef
70.
Buchanan FG, Gorden DL, Matta P, Shi Q, Matrisian LM, DuBois RN (2006) Role of β-arrestin1 in the metastatic progression of colorectal cancer. Proc Natl Acad Sci USA 103:1492–1497PubMedCrossRef
71.
Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS (2002) Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 8:289–293PubMedCrossRef
72.
Shao J, Lee SB, Guo H, Evers BM, Sheng H (2003) Prostaglandin E2 stimulates the growth of colon cancer cells via induction of amphiregulin. Cancer Res 63:5218–5223PubMed
73.
Subbaramaiah K, Benezra R, Hudis C, Dannenberg AJ (2008) Cyclooxygenase-2-derived prostaglandin E2 stimulates Id-1 transcription. J Biol Chem 283:33955–33968PubMedCrossRef
74.
Al-Salihi MA, Ulmer SC, Doan T, Nelson CD, Crotty T, Prescott SM, Stafforini DM, Topham MK (2007) Cyclooxygenase-2 transactivates the epidermal growth factor receptor through specific E-prostanoid receptors and tumor necrosis factor-α converting enzyme. Cell Signal 19:1956–1963PubMedCrossRef
75.
Oshima H, Popivanova BK, Oguma K, Dong D, Ishikawa T, Oshima M (2011) Activation of epidermal growth factor receptor signaling by the prostaglandin E2 receptor EP4 pathway during gastric tumorigenesis. Cancer Sci 102:713–719PubMedCrossRef
76.
Mochizuki S, Okada Y (2007) ADAMs in cancer cell proliferation and progression. Cancer Sci 98:621–628PubMedCrossRef
77.
Oshima H, Itadani H, Kotani H, Taketo MM, Oshima M (2009) Induction of prostaglandin E2 pathway promotes gastric hamartoma development with suppression of bone morphogenetic protein signaling. Cancer Res 69:2729–2733PubMedCrossRef
78.
Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2:127–137PubMedCrossRef
79.
Mann JR, Backlund MG, Buchanan FG, Daikoku T, Holla VR, Rosenberg DW, Dey SK, DuBois RN (2006) Repression of prostaglandin dehydrogenase by epidermal growth factor and snail increases prostaglandin E2 and promotes cancer progression. Cancer Res 66:6649–6656PubMedCrossRef
80.
Myung SJ, Rerko RM, Yan M, Platzer P, Guda K, Dotson A, Lawrence E, Dannenberg AJ, Lovgren AK, Luo G, Pretlow TP, Newman RA, Willis J, Dawson D, Markowitz SD (2006) 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci USA 103:12098–12102PubMedCrossRef
81.
82.
83.
Esquela-Kerscher A, Slack FJ (2006) Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer 6:259–269PubMedCrossRef
84.
85.
86.
Sonkoly E, Pivarcsi A (2011) MicroRNAs in inflammation and response to injuries induced by environmental pollution. Mutat Res 717:46–53PubMedCrossRef
87.
O’Connell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D (2007) MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci USA 104:1604–1609PubMedCrossRef
88.
Tili E, Michaille JJ, Cimino A, Costinean S, Dumitru CD, Adair B, Fabbri M, Alder H, Liu CG, Calin GA, Croce CM (2007) Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-α stimulation and their possible roles in regulating the response to endotoxin shock. J Immunol 179:5082–5089PubMed
89.
Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk ML, Struhl K (2010) STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell 39:493–506PubMedCrossRef
90.
Kong D, Piao YS, Yamashita S, Oshima H, Oguma K, Fushida S, Fujimura T, Minamoto T, Seno H, Yamada Y, Satou K, Ushijima T, Ishikawa T, Oshima M (2012) Inflammation-induced repression of tumor suppressor miR-7 in gastric tumor cells. Oncogene 31:3949–3960PubMedCrossRef
91.
Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103:2257–2261PubMedCrossRef
92.
Sachdeva M, Zhu S, Wu F, Wu H, Walia V, Kumar S, Elble R, Watabe K, Mo YY (2009) p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci USA 106:3207–3212PubMedCrossRef
93.
Kefas B, Godlewski J, Comeau L, Li Y, Abounader R, Hawkinson M, Lee J, Fine H, Chiocca EA, Lawler S, Purow B (2008) MicroRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res 68:3566–3572PubMedCrossRef
94.
Reddy SD, Ohshiro K, Rayala SK, Kumar R (2008) MicroRNA-7, a homeobox D10 target, inhibits p21-activated kinase 1 and regulates its functions. Cancer Res 68:8195–8200PubMedCrossRef
95.
Webster RJ, Giles KM, Price KJ, Zhang PM, Mattick JS, Leedman PJ (2009) Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7. J Biol Chem 284:5731–5741PubMedCrossRef
96.
Jiang L, Liu X, Chen Z, Jin Y, Heidbreder CE, Kolokythas A, Wang A, Dai Y, Zhou X (2010) MicroRNA-7 targets IGF1R (insulin-like growth factor 1 receptor) in tongue squamous cell carcinoma cells. Biochem J 432:199–205PubMedCrossRef
97.
Saydam O, Senol O, Wurdinger T, Mizrak A, Ozdener GB, Stemmer-Rachamimov AO, Yi M, Stephens RM, Krichevsky AM, Saydam N, Brenner GJ, Breakefield XO (2011) miRNA-7 attenuation in schwannoma tumors stimulates growth by upregulating three oncogenic signaling pathways. Cancer Res 71:852–861PubMedCrossRef
Metadata
Title
The role of PGE2-associated inflammatory responses in gastric cancer development
Authors
Hiroko Oshima
Masanobu Oshima
Publication date
01-03-2013
Publisher
Springer-Verlag
Published in
Seminars in Immunopathology / Issue 2/2013
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI
https://doi.org/10.1007/s00281-012-0353-5

Other articles of this Issue 2/2013

Seminars in Immunopathology 2/2013 Go to the issue

Review

Mast cells and inflammation-associated colorectal carcinogenesis

Introduction

Introduction for inflammation and cancer

Review

Resolution of inflammation as a novel chemopreventive strategy

Review

Protumor and antitumor functions of neutrophil granulocytes

Review

Involvement of inflammatory factors in pancreatic carcinogenesis and preventive effects of anti-inflammatory agents

Review

Multifaceted roles of PGE2 in inflammation and cancer
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits